To evaluate the role of pelvic MRI in diagnosis and assesment of combined surgical and infliximab treatment of perianal Crohn's disease (PACD). METHOD: 24 patients with signs of PACD were prospectively evaluated. They were previously treated with azathyoprin for a period of 6 months to 7 years and antibiotics and than started on Infliximab 5 mg/kg (IFX) at 0,2 and 6 weeks induction protocol. Luminal CD activity was assesed by colonoscopy. Perianal Disease Activity Index (PDAI) was calculated to evaluate perianal fistulae activity. Surgical examination under anesthesia (EUA) was performed and noncutting seton placed where appropriate. Pelvic MRI was performed in each patient before Infliximab treatment, and in half of the patients after IFX. MRI criteria were used to asses activity and remission of PACD. RESULTS: 14/24(58.5%) patients had ileocolitis, 10/24 (41.5%) colitis, and in 22/24(91.7%) rectum was affected. Median disease duration was 5.5+2.5 years. MRI revealed simple fistula in 4/24 (16.7%) and complex fistula in 20/24 (83.3%) patients. Abscess was present in 19/24(79%) patients. Enterocutaneous and recto-vaginal fistula was found in 2(8.3%) and 3(12.5%) patients, respectively. Median PDAI before and 8 weeks after IFX treatment was 8.3+2.08 and 3.5+1.03, respectively (p=0.00064). Incomplete response (reduction fistulae drainage by 50%) was found in 10/24(42%) patients, complete response (no drainage) in 11/24 (46%) patients, while in 3/24(12.5%) new fistula opened. Control pelvic MRI was performed in 13/24 (54%) patients. Of those, 9/13(69%) had complete remission according to MRI criteria. Seton was removed after second IFX dose in 15/24 (62.5%) patients and placed again in 2/24 (8%) patients 4 months after completion of IFX treatment.
INTRODUCTION
Perianal fistulas and abscesses are the most frequent perianal lesions in the patients with Crohns disease (CD) 1 . Fistula occurs in 48% of patients with CD, so one half of the patients with CD have perianal fistula. Nine percents of this group have a recto-vaginal fistula. One quarter of patients (26%) develope fistula after 20 years duration of disease. The majority of patients with perianal disease (92%) have colonic disease with rectal involvement 2 . Combined perianal lesions are the most common findings in CD patients. 36-81% CD patients have combined findings of fissure, abscess and fistula. The isolated fistula could be found in only 5% of CD patients [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Examination Under Anestesia (EUA), performed by the experienced colorectal surgeon and pelvic Magnetic Resonance Imaging (MRI) have been cosidered the gold standard for assessing fustula. The diagnostic accuacry of surgical examination under anesthesia (EAU) reaches 92% in the detection and correct classification of fistula, abscess and sinus tracts. It involves visual inspection, palpation, and/or passage of various probes into the fistula while the patient is under general anesthesia 12 . The diagnostic accuracy of MRI reaches 76-100%. The MRI assessment may change the initial surgical decision and menagement in aproximately 10-15% of cases. A combination of these two diagnostic procedures incrases accuracy up to 100%. The diagnostic accuracy of endoanal ultrasonography (EUS) ranges from 56-100% . The application of EUS is often limited esspecially in the group of patient with associated rectal inflamation and/or stricture and anal canal stenosis. To achieve optimal accuracy, EUS should be performed only by well educated and experienced ultrasoundsonographist. Compared to EUS, MRI shows hidden interspfinteric space, often filled with pus, even whithout visible external fistula openings.
Although pelvic computerized tomography (CT) is able to provide visualisation, its usfulness in the assesment of perianal fistula remains still not clear. CT has limited resolution in distinguishing between soft tissue and inflammatory streaking. Sometimes, the inner opening of fistula tract is not shown by CT immaging .Vascular structures in perirectal fat tissue can be misinterpreted as fistula tracts. CT scan may have a little accuracy in identifying the levator ani muscle, making visualisation of supralevatoric or ishiorectal abscessus very difficult.
The advantages of MRI are numerous 13. Pelvic MRI scans show the fistula opening in the intestinal wall, surrounding muscle, skin and visceral layers. MRI identifies relationship of fistula or abscess with m.levator ani very well. However, neural and vascular structures of perineum (pudendal and lower gluteal artery) may be sometimes misinterpreted as fistula tract.
There were several attempts of forming MRI criteria for the assessment of fistula activity in perianal CD [13] [14] . According to the MRI findings and Parks classification, fistulas may be classified as simple or complex 16 . Crohn's DiseaseActivity Index (CDAI) 17 is not suitable for measuring fistula activity.
The Perianal Disease Activity Index (PDAI) 18 evaluates 5 categories affected by fistulas: discharge, pain, restriction of sexual activity, type of perianal disease, and degree of induration. Each category is graded on a 5-point Likert scale ranging from no symptoms (score of 0) to severe symptoms (score of 4). Minimal PDAI score is <5 19 and maximal may be <20. A higher score indicates more severe disease. The Perianal Disease Activity Index (PDAI) (may become in the future the perianal disease equivalent of the Crohn's Disease Activity Index (CDAI)) has yet to be fully validated.
In clinical practice the Fistula Drainage Assessment (FDA) has been used most freequently. A fistula is open and actively draining if the investigator can express purulent material from the fistula with the application of gentle pressure. The effects of therapy are assessed by determining the number of closed fistula and by the time to loss of complete fistula closure. Partial response is defined as closure of at least 50% of fistulas present at baseline, maintained for at least 4 weeks. Complete response is defined as closure of all fistulas present at baseline, maintained for at least 4 weeks 19 . The standard medication therapy for treatment of perianal CD are immunosuppressive drugs (azathioprine, 6-merkaptopurin) 20, 22 and antibiotics (metronidazole and ciprofloxacin) 23, 24 . The current clinical practice of using these medications is based on a meta-analysis of 5 controlled trials in which fistula closure was examined as a ACCENT II 25 results showed the beneficial effect of IFX as maintenance therapy in cessation of fis-tula drainage. The time to loss of response was 40 weeks versus 14 weeks in the infliximab maintenance group ver-sus the placebo group, respectively. Thirty-six percent of the patients in the infliximab group maintained cessation of drainage at week 54 compared to 19% of the placebo group.
More recently a combined surgical and medical approach has been shown to be extremely effective for the treatment of complex fistulae. The commonest acute surgical procedure is incision and drainage of perianal abscess. Optimal surgical menagement depends on the endoscopic activity of recto sigmoid mucosa, type and localisaton of fistula. Fistulotomy is not ideal procedure because of the high percentage of folowing proctectomy 26 . Noncutting Setons are the treatment of choice even in the patients with low fistulas and active inflammation of rectosigmoid colon 27 . Noncutting Seton maintains drainage of the fistula, thereby reducing perifistular inflammation. When the fistula tracts width becomes approximately equal to the Seton diameter, Seton can be removed or replaced by a smaller caliber. Seton may cause mild pressure and the compressive necrosis but never leads to incontinence 27, 28 .
MATERIALS AND METHODS:
A prospective study of 24 CD patients diagnosed in University Clinical Hospital Zvezdara was performed. The diagnosis of CD was based on standard clinical, radiological, endoscopic, and histological criteria. All patients had perianal disease with one or more active fistula and/or perianal abscess. The maintenance therapy was based on immunosuppressant and antibiotics.
Standard examination of perianal region (inspection and palpation in order to assess perianal abscess, open external fistula and drainage activity) was performed in all patients before surgical and MRI evaluations. Luminal disease activity was evaluated by flexibile sigmoidoscopy or colonoscopy, depending on the extent of disease at the last assessment.
For the purpose of clinical evaluation of fistula activity Perianal Disease Activity Index (PDAI) and Fistula Drainage Activity (FDA) was calculated. The values of PDAI are shown in Table 1 . Both indexes were assesed before combined surgical and biologic treatment, and 8 weeks after the third induction dose of infliximab. PDAI values more than 5 were indicator of the disease relapse. The effect of treatment was also evaluated by number of fistulas whithout active drainage. Partial response is defined as a cessation of secretion and induration in at least 50% of fistulas presented at baseline.
Pelvic MRI was performed in all 24 patients before medical and surgical treatment. The MRI was performed by Magnet device Siemens Avanto 1.5 T in T1W sequences in axial and sagittal planes. Thirteen patients were reassessed after 8 weeks -6 months from the third induction dose of infliximab. Based on the MRI findings (radiologist report) fistulas were classified in two groups: 1. Simplex fistula (superficial and low intersphincteric) with simple tract and no findings of abscess. 2. Complex fistulas (intersphincteric, transsphincteric, suprasphincteric and end extrasphincteric) with multiple tracts and/or presence of abscesses. According to MRI results complete response was defined as an absence of abscess, reduction of bowel wall edema and complete fibrosing of fistula tract present at baseline. Partial response was considered as partial fistula tract closure with the absence of abscess and intestinal wall oedema, but with the presence of mild perilimphangitis.
All patients, apart from the type of perianal fistulas, were surgically treated. Examination under anesthesia (EUA) was performed in all patients. EUA was consisted of the visual inspection, palpation, the passage of malleable probes into fistula tracks, incision and drainage of perianal abscess and placement of Noncutting Setons under general anesthesia. EUA was performed by an experienced co- 
was placed to all patients regardless to type of fistula. All patients with simple fistula had severe active rectal inflamation, so they were surgically treated with Noncutting Setons placement instead of fistulectomy.
Seton was left a long enough, depending on the clinical response to combination therapy, but no longer than 6 months after the third induction dose of infliximab. Seton was removed when the dreinage was completly reduced and fistula tracts width became approximately equal to the Seton diameter.
All patients were treated with immunosuppressive therapy (azathioprin) from 6 months to 7 years. Antibiotics (metronidazole and ciprofloxacin) were prescribed periodically, especially during the episode of inflammati-on. All patients received at least, the induction dose of infliximab (5mg/kg at 0, 2 and 6 weeks). For statistical analysis descriptive methods and student's t-test (at the level of statistical significance p <0.05) were used. Analysis was carried out using 3.0 GrafPad INSTAT statistical programs.
PATIENTS, STUDY DESIGNE AND RESULTS
We have included 24 patients with perianal Crohn's disease (6 females and 18 males, median age 33+10 years, range 19-57). Median disease duration was 5.5+5.7 years (range 1-26). According to Montreal classification, the majority of patients (14/24 or 58.5%) had ileocolitis and 10/24 (41.5%) had colitis. All, except 2 patients had rectum involved (91.7%). The patients' characteristics are shown in Table 1 .
Pelvic MRI was performed in all patients. Superficial and low trans-sfincteric fistula was found in 4/24 (16.7%) and complex fistula in 20/24 (83.3%) patients (Figure 1 ). Concomitant abscess was diagnosed in 19/24 (79%) patients, of which 2 were in superficial fistula subgroup. Enterocutaneous fistula was found in 2/24 (8.3%) and rectovaginal fistula in 3/24 (12.5%) patients. Single fistula was seen in 4/24 (16.7%) patients, while combined perianal fistula was present in 15/24 (62.5%). Combined finding of fistula and abscess together was found in 12/24 (80%) patients ( Figure 2) . Two patients had both perianal and enterocutaneous fistula with abscess. One patient had combination of perianal, enterocuatneous and rectovaginal fistula with abscess, and the other one had perianal and rectovaginal fistula together. Characteristics of perianal lesions in our patients are shown in Table 2 .
Perianal Crohn's disease activity index (PDAI) was calculated in all patients before and after combined treatment (Table 3) . Cutoff value for remission/relaps was £ 5. PDAI before starting Infliximab therapy was 8.3+2 (median 8, range 0 -20), and 3.5+1 (median 3) 8 weeks after third Infliximan induction dose (p < 0.001). Fistula drainage was evaluated by physical examination in all patients. After Infliximab induction treatment 11/24(46%) patients had complete response, 10/24 (42%) had incomplete response and 3/24 (12.5%) developed new fistula. Pelvic MRI was performed in 13/24 patients. Complete remission was seen in 9/13 (69%) patients and incomplete response in 4/13 (31%). Complete MRI remission was defined as finding of fibrous fistula tract, with no abscess and bowel wall edema (Figure 3) , while incomplete response was defined as partial fibrosis of fistula tract, with no abscess and bowel wall edema (Figure 4) . Noncutting seton was placed in all 24 patients. The time from seton placement to its removal depended on clinical response. The seton was removed after the first Infliximab induction dose in 2/24 patients, after the second dose in 15/24 (62%), and after the third induction dose in 7/24(29%) pa- (Table 4 ). Based on surgical evaluation at the time of seton removal, 15/24 (62.5%) of our patients had complete clinical response (no spontaneous or mild fistula drainage on mild digital compression) with fistula closure after the second Infliximab induction dose.
DISCUSSION
According to duration of CD, the incidence of fistula appearance is 12%, 15%, 21% and 26% after 1, 5, 10 and 20 years, respectively 11 . According to CD extent, 12% of patients with involved terminal ileum have concomitant fistula, 15% with ileocolitis, 41% with colitis and spared rectum, and 92% with colitis and involved rectum 12 . The majority of our patient cohort had ileocolitis with involved rectum and perianal disease, and they had clinically active luminal disease. In literature, 36-81% of patients with perianal CD have combined perianal lesions (fissure, fistula and abscess), while only 5% have single perianal lesion [5] [6] [7] [8] [9] [10] . That was not the case in our cohort, where 16.7% of patients had single perianal lesion, which generally indicates mild CD.
Surgical fistula treatment depends of CD luminal activity based on endoscopy finding, fistyla type and localisation [26] [27] [28] [29] [30] [31] [32] . Fistulotomy is indicated only in low fistula in the setting of luminal disease remission, when fistula closure rate is up to 100% 11, 26 . Current surgical opinion in low perianal fistula treatment in active luminal disease is non-cutting seton placement, which was the case in our cohort. Serious postoperative complicasions can be expected if the low fistula fistulotomy is performed in active luminal disease (proctectomy with colostoma in up to 60% of patients, and incontinence in 50%) 15, 16 . In CD patients with "high" fistula and active luminal disease the recommended procedure is non-cutting seton placement, as well as in patients having complex fistula and non-active luminal disease 17, 33, 34, 35 . Seton should be removed as soon as perifistulous inflammation is under control, fistula drainage is diminished and fistula tract calibar is narrowed approximately to seton calibar. Scott et al 18 reported that 85% od 27 patients closed fistula with non-cutting seton, while 39% needed repeated seton placement due to relapse of fistula drainage.
Efficacy of antibiotic treatment is not proved by randomized placebo controlled trials. However, a number of authors reported efficacy of metronidazol and ciprofloxacin 23, 24 . Azathyoprin/6MP is standard treatment for perianal CD in published CD consensus 19, 20 . Other immunosupressants (like cyilosporin and tacrolimus) did not show consistent response rate 21, 22 (Table 5 ). In one of two randomized placebo controlled study 19, 25 of Infliximab efficacy in perianal fistula treatment 85/94 patients were started on Infliximab induction regimen. Partial response at week 4 was achieved in 68% of patients at dose of 5 mg/kg, 56% at 10 mg/kg and 26% in placebo group. The complete response at week 8 was 55% (5 mg/kg), 38 % (10 mg/kg) and 11% (placebo group), while in 11 patients an abscess formation occurred during Infliximab treatment. In ACCENT II study 21 306 patients with active fistula drainage was treated with Infliximab induction protocol. Complete clinical response was found in 69% of patients. The rest of the group with incomplete clinical response were randomized in 2 groups at week 14: the placebo group and the group that continued with Infliximab maintenance treatment every 8 week during 54 weeks period. 39% of patients in Infliximab maintenance treatment group had complete fistula closure, while only Br. 3 The role of pelvic MRI in assesment of combined surgical 93 and Inflximab treatment for perianal Crohn's disease 19% in placebo group. Duration of sustained clinical remission was 14 weeks in placebo group and 3 40 weeks in maintenance treatment group (p< 0.001). However, the majority of maintenance group patients needed surgical intervention during Infliximab maintenance treatment. Our results showed that 46% of patients had complete clinical response after Infliximab induction treatment, while 62% had non-cutting seton removed after the second Infliximab induction dose, meaning that fistula drainage at that time was minimal or absent. Control pelvic MRI findings showed that 69% of our patients had closed fis-tula tract, which was almost completely in accordance with surgical decision for seton removal (62%). This is in accordance with published literature 36 . Somewhat lower clinical response in our cohort (46% compared to 69% in ACCENT II study) could be due to large number of our patients who had complicated fistulas and due to fact that 80% of our patients had concomitant perianal abscess before onset of Infliximab treatment.
One of the main biologic treatment (Infliximab in this case) side-effects is increased incidence of infections. Only 2 of our patients had repeated abscess formation 4 months after Infliximab treatment and seton removal. At the time of our study conduction we were not in a position to continue with Infliximab maintenance protocol in our patients.
In conclusion, our results showed that combined Infliximab induction and surgical treatment could be recommended in patients with perianal and active luminal CD. Clinical response rate was highest after the second IFX induction dose, confirmed by pelvic MRI and surgical decision to remove seton. Pelvic MRI and EUA are the "gold" standards in diagnosis, treatment approach and evaluation of treatment effect in patients with perianal CD. EUA and seton placement are the basic procedures in treating perianal CD, specially before initiating biologic therapy.
SUMMARY ULOGA MAGNETNE REZONANCE (MR) U DIJAG-NOZI I OCENI EFEKTA KOMBINOVANE HIRURŠKE I MEDIKAMENTOZNE TERAPIJE U LECENJU PERI-ANALNE FISTULOZNE FORME CROHN-OVE BOLESTI
Cilj rada: Ulogu magnetne rezonance (MRI) u dijagnostici, planiranju hirurškog pristupa le~enju i oceni efekata medikamentoznog le~enja perianlne fistulozne forme Crohn-ove bolesti (PCB) Materijal i metodi: Prospektivno smo pratili 24 pacijenta sa klini~kim znacima PCB koji su u trajanju od 6 meseci do 7 god. bili prethodno na terapiji azatioprinom i antibioticima. Luminalna aktivnost bolesti procenjivana je kolonoskopski. Za klini~ko pra}enje aktivnosti fistule koristili smo PDAI skor. MRI pregled male karlice radjen je svim pacijentima pre terapije Infliksimabom kao i hirur{ki pregled pod anestezijom sa plasiranjem "noncuting" setona. Kod 13/24 (54%) pacijenata uradjen je i kontrolni MRI pregled posle terapije. Koriš}eni su MRI kriterijumi za ocenu aktivnosti i remisije bolesti. Svi pacijenti su dobijali infliximab u indukcionoj dozi, 5mg/kg tt 0, 2, 6 nedelje.
Resultati: 14/24 (58.5%) je imalo ileokolitis; 10/24 (41.5%) Crohn kolitis a 22/24 (91.7%) pacijenata je imalo zahva}en rektum. Prose~no trajanje bolesti je iznosilo 5,5g. MRI nalazom je nadjeno da prostu simplex fistulu ima 4/24 (16,7%) pacijenata dok je 20/24 (83.3%) imalo kompleksnu fistulu. Apsces je nadjen u 19/24 (79%) pacijenata. Enterokutana i rektovaginalna fistula je nadjena kod 2(8.3%), odnosno 3(12.5%) pacijenta. Vrednost PDAI pre zapo~injanja terapije Infliximab-om iznosila je 8.3+2.08, odnosno 3.5+1.03 osam nedelja nakon tre}e indukcione doze Infliximaba (p<0.001). Parcijalni odgovor meren drena'nom aktivnosti fistule imalo je 10/24 (42%) pacijenata; kompletan 11/24 (46%) dok je 3/24 (12.5%) pacijenta razvilo novu fistulu. Kontrolni MRI pregled posle terapije Infliksimab-om uradjen je u 13/24 pacijenata. Od toga 9/13 (69%) imalo je kompletnu remisiju po MRI kriterijuma. Kod 15 /24 (62,5%) pacijenata nakon druge indukcione doze uklonjen je seton. Kod 2/24 (8%) pacijenta seton je ponovo vra}en 4 meseca nakon biološke terapije.
Zaklju~ak : MRI pregled male karlice kod pacijenata sa PCB pre i posle terapije Infliximab-om je veoma va'an u dijagnozi i lokalizaciji perianalne fistule, planiranju na~i-na le~enja, otkrivanju inflamatornih komplikacija kao i oceni efekta terapije. Hirurška odluka o uklanjanju setona je bila u saglasnosti sa objektivnom MRI procenom o remisiji PCB.
Klju~ne re~i: Chron-ova bolest, perianalna fistula, MR, Infliximab
